Gentium SpA Stock Upgraded (GENT)

NEW YORK ( TheStreet) -- Gentium SpA (Nasdaq: GENT) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:
  • GENT's debt-to-equity ratio is very low at 0.12 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, GENT has a quick ratio of 1.90, which demonstrates the ability of the company to cover short-term liquidity needs.
  • Net operating cash flow has significantly increased by 281.60% to $0.39 million when compared to the same quarter last year. In addition, GENTIUM SPA -ADR has also vastly surpassed the industry average cash flow growth rate of -6.24%.
  • The gross profit margin for GENTIUM SPA -ADR is rather high; currently it is at 68.40%. Regardless of GENT's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, GENT's net profit margin of -0.40% significantly underperformed when compared to the industry average.
  • GENTIUM SPA -ADR has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past year. However, we anticipate this trend reversing over the coming year. During the past fiscal year, GENTIUM SPA -ADR reported lower earnings of $0.23 versus $0.36 in the prior year. This year, the market expects an improvement in earnings ($0.72 versus $0.23).
.

Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. The company has a P/E ratio of 22.3, below the average drugs industry P/E ratio of 23.8 and above the S&P 500 P/E ratio of 17.7. Gentium SpA has a market cap of $101.6 million and is part of the health care sector and drugs industry. Shares are up 38.2% year to date as of the close of trading on Wednesday.

You can view the full Gentium SpA Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff
null

If you liked this article you might like

Biotech 2013 by the Numbers: A Blockbuster Year

3 Biotech Stocks Spiking on Big Volume

3 Health Care Stocks Spiking on Big Volume

Trade-Ideas: Gentium SpA (GENT) Is Today's New Lifetime High Stock

4 Stocks Triggering Breakout Trades